Cough - Pipeline Review, H2 2020

August 2020 | 116 pages | ID: C4D3EBD6A43EN
Global Markets Direct

Abstracts

Cough - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough - Pipeline Review, H2 2020, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or a sour taste in mouth. Risk factors include laryngopharyngeal reflux, allergies, reduced hydration, smoking, asthma, chronic bronchitis, gastroesophageal reflux and chemical sensitivities. Treatment for cough includes antihistamines, decongestants, antibiotics and cough suppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cough - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 9, 4, 10, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Cough - Overview
Cough - Therapeutics Development
Cough - Therapeutics Assessment
Cough - Companies Involved in Therapeutics Development
Cough - Drug Profiles
Cough - Dormant Projects
Cough - Discontinued Products
Cough - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Cough, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Cough - Pipeline by Adare Pharmaceuticals Inc, H2 2020
Cough - Pipeline by Algernon Pharmaceuticals Inc, H2 2020
Cough - Pipeline by Alitair Pharmaceuticals Inc, H2 2020
Cough - Dormant Projects, H2 2020
Cough - Dormant Projects, H2 2020 (Contd..1), H2 2020
Cough - Dormant Projects, H2 2020 (Contd..2), H2 2020
Cough - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cough, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Adare Pharmaceuticals Inc
Algernon Pharmaceuticals Inc
Alitair Pharmaceuticals Inc
Antheia Inc
Asana BioSciences LLC
Axalbion SA
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
BELLUS Health Inc
Charleston Laboratories Inc
Conrig Pharma ApS
Evotec SE
Grunenthal GmbH
Hyundai Pharma Co Ltd
Korea United Pharm Inc
Merck & Co Inc
NeRRe Therapeutics Ltd
Nocion Therapeutics Inc
Nuformix Plc
PhytoHealth Corp
Shionogi & Co Ltd
SolAeroMed Inc
Trevi Therapeutics Inc
Tris Pharma Inc